BioNTech’s mRNA Immunotherapy Misses Progression-Free Survival Goal in HPV-Related Head and Neck Cancer Trial

Topline results: BNT113 + pembrolizumab did not significantly improve PFS vs pembrolizumab alone in HPV16+ HNSCC. Trial proceeds to OS readout.